Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,452

Document Document Title
WO/2019/051396A1
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...  
WO/2019/026004A3
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-( (2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to ...  
WO/2019/042301A1
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...  
WO/2019/040706A1
Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be selected from 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyr imidin-4-yl)amino)benzo[d]oxazol-2(...  
WO/2019/034468A1
Process for the preparation of a compound with at least one monothiocarbonate group by reacting: - a compound with at least one mercaptoalcohol group and - a dialkylcarbonate, in the presence of a catalyst wherein the catalyst is a salt ...  
WO/2019/026728A1
[Problem] The purpose of the present invention is to provide an organic EL element in which, as a highly efficient and highly durable organic EL material, various materials excelling in electron injection/transport performance, hole bloc...  
WO/2019/026004A2
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-( (2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to ...  
WO/2019/023147A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...  
WO/2019/023145A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...  
WO/2019/012173A1
The present invention relates to piperidine derivatives as inhibitors of the PDE8A enzyme. Therefore, said compounds can be used in the production of a drug for the treatment and/or prevention of diseases involving PDE8A, such as neurode...  
WO/2019/011176A1
Disclosed is the use of a 2-trifluoromethylbenzenesulfonamide derivative as shown in formula (I) as a URAT1 inhibitor, in particular as a therapeutic agent for a disorder related to abnormal uric acid levels.  
WO/2019/000494A1
Provided is a fluorene-based organic electroluminescent compound, having the following structure: The compound has good thermal stability, high luminous efficiency, and high luminous purity, and can be used for manufacturing organic elec...  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/230528A1
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...  
WO/2018/214932A1
Small molecule compounds having aggregation-induced emission (AIE) characteristics. The compounds include organic, aromatic salts having anion-π+ interactions. In some embodiments, the anion-π+ interactions can include heavy-atom-anion...  
WO/2018/216921A2
The present invention relates to a novel compound and an organic electroluminescent element comprising the same, and as the compound according to the present invention is used in an organic material layer, preferably a light emitting lay...  
WO/2018/216921A3
The present invention relates to a novel compound and an organic electroluminescent element comprising the same, and as the compound according to the present invention is used in an organic material layer, preferably a light emitting lay...  
WO/2018/213140A1
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...  
WO/2018/213150A1
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...  
WO/2018/204987A1
Compounds are provided which are inhibitors of the CAXII enzyme. Due to the interaction between CAXII and Pgp, such compounds may be useful in lowering the chemoresistance of a cancer allowing for co-administration with existing anti-can...  
WO/2018/205948A1
Provided are benzoxazolinone sulfonamide derivatives that inhibit Na v1.7 activity, pharmaceutical compositions containing them and their use in therapy for the treatment of diseases mediated by Na v1.7 activity.  
WO/2018/187845A1
The present invention relates to certain heterocyclic compounds of formula (1) that have the ability to inhibit lysine biosynthesis via the diaminopimelate biosynthesis pathway in certain organisms. As a result of this activity these com...  
WO/2018/187414A1
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.  
WO/2018/187506A1
Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such comp...  
WO/2018/187324A1
The subject invention relates to a process of prepating (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying wit...  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/177865A1
The present invention relates to the use of compounds having an anti- heparanase activity of formu la [R - L1- Ar1- L - Ar]2- X, wherein X is selected from the group consisting of SO2, C1 -C4 a lkylene, linear or branched, and wherein Ζ...  
WO/2018/176343A1
Compounds of Formula (A), where the definition of the variables are as described in the description, as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as modulators of dysfun...  
WO/2018/177857A1
The present invention relates to symmetrical 2-aminophenyl-benzazolyl-5-acetate compoundsof formula (I). Such compounds are endowed with an anti-heparanase activity. The present invention also relates to the use of such compounds as a me...  
WO/2018/183626A1
Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.  
WO/2018/177860A1
The present invention relates to 2-(4-(4-(bromo-methoxybenzamido)benzylamino) phenyl)benzazole derivatives of formula (I) having an anti-heparanase activity. The invention also relates to the use of such compounds as a medicament, in par...  
WO/2018/175185A1
The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at ...  
WO/2018/172423A1
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...  
WO/2018/171942A1
It is disclosed a process for obtaining phenolic derivatives with high industrial interest in the pharmaceutical industry by using glycerol carbonate. Specifically, the process provides for a phenol substituted in position 2 to react wit...  
WO/2018/165501A1
The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORγ activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonami...  
WO/2018/164184A1
Disclosed is a compound selected from among aniline derivatives represented by formula (1) and naphthalene derivatives represented by formula (2), or a salt thereof. (In the formulae, each of R1 and R2 independently represents a hydrogen...  
WO/2018/152949A1
The present invention relates to a method for preparing optically pure (R)-4-n-propyl-dihydrofuran-2(3H)-one, and belongs to the field of chemical synthesis. The method of the present invention uses the steps of alkylation, reduction, cy...  
WO/2018/155942A1
The present disclosure relates to a plurality of host materials and an organic electroluminescent device comprising the same. The organic electroluminescent device of the present disclosure can exhibit excellent lifespan characteristics ...  
WO/2018/157043A1
Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.  
WO/2018/156500A1
Methods of synthesizing polyfluorinated amino acid derivatives are disclosed, along with polyfluorinated amino acid derivatives produced from said methods, as well as compositions containing same. The synthesis methods utilize an oxazolo...  
WO/2018/151470A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present disclosure is contained in an electro...  
WO/2018/148745A1
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...  
WO/2018/141854A1
The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity ...  
WO/2018/143638A1
The present invention relates to a 4'-phosphopantetheinyl transferase enzyme inhibitor derived from Mycobacterium tuberculosis, and a pharmaceutical composition for preventing or treating tuberculosis, containing the same as an active in...  
WO/2018/136890A1
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...  
WO/2018/133870A1
A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.  
WO/2018/131690A1
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...  
WO/2018/122549A1
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, • B is a saturated or partially unsaturated monocyclic or bicyclic, heterocyclic group optionally substituted...  
WO/2018/122550A1
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: • B is an aryl or heteroaryl group optionally substituted by one or more R10 groups; and * X is sele...  
WO/2018/109496A2
The present invention relates to a process for the preparation compounds of Formula (I): Formula (I) wherein X, Z, Q, Ar, R1, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparation o...  

Matches 1 - 50 out of 12,452